Humacyte: Upside Potential, But I Will Wait For Revenue Trends

2025-01-25 03:04:47 ET

Summary

• Humacyte's stock remained depressed post-Symvess approval due to FDA delays and distressed financing, despite positive data and market potential.
• The company’s precarious cash position, exacerbated by fundraising from Lincoln Park and other investors, hindered stock recovery.
• Symvess, priced at $29,500 per unit, offers a cost-effective alternative for vascular trauma, with high patency and low infection rates.
• I see potential upside as HUMA starts generating revenue and progresses with AV fistula approval, but financial risks and potential dilution remain.

...

Read the full article on Seeking Alpha

For further details see: